or Login to see your representatives.

Access Candidates' and Representatives' Biographies, Voting Records, Interest Group Ratings, Issue Positions, Public Statements, and Campaign Finances

Simply enter your zip code above to get to all of your candidates and representatives, or enter a name. Then, just click on the person you are interested in, and you can navigate to the categories of information we track for them.

Public Statements

House Passes Bipartisan Rogers Bill to Strengthen Pediatric Drug Research

Press Release

By:
Date:
Location: Washington, DC

Today the House of Representatives overwhelmingly passed a bipartisan bill written by U.S. Rep. Mike Rogers, MI-08, that would create a permanent structure for strengthening the testing of pediatric drugs and improving their safety.

Rogers, a senior member of the House Energy and Commerce Committee, introduced the bill (H.R. 4274) with Representatives Anna Eshoo (D-CA) and Ed Markey (D-MA). The bill would reauthorize the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) and was passed by the House as part of the Food and Drug Administration Reform Act of 2012 (H.R. 5651).

"Understanding how drugs work in children is a difficult scientific task, yet children depend on many of the same life-saving treatments used regularly by adults," Rogers said. "BPCA and PREA have led to 180 new drugs being studied in kids, and more than 400 labels have been updated with critical pediatric information, leading to more information about pediatric drug safety, effectiveness, dosing and formulations. Permanent reauthorization of these laws will help the FDA, drug manufacturers, and physicians provide safer treatments for children of all ages."

Congress originally passed BPCA in 1997 to provide incentives for researchers to conduct more clinical trials of certain drugs in children. Congress also passed PREA in 2003 to give the FDA authority to require pediatric testing as part of the new drug review and approval process. These laws are scheduled to expire this year, and Rogers' legislation makes both successful programs permanent.

Rogers' legislation would also enact new reforms to strengthen both BPCA and PREA. These include new tools for the FDA to ensure pediatric studies are completed on time, increased transparency about the status of ongoing pediatric studies, and a greater focus on the safety of drugs for infant children. The bill has been endorsed by numerous organizations, including physician, patient, and industry groups.

The Senate has passed similar legislation (S. 3187), and differences between the bills must be resolved before being sent to the president for his signature.


Source:
Back to top